Table 1. Summary of CTCL patients’... | American Society of Hematology

Table 1.

Summary of CTCL patients’ peripheral blood flow cytometric parameters

Pt ID	Sorted abnormal cell population	TCR-Vβ⁺	Vβ gene identified	PCR⁺	CD4:CD8 ratio	CD4⁺CD7⁻, %	CD4⁺CD26⁻, %	Stage
1	CD3⁺CD4⁺CD7⁻CD26⁻	Yes	20	Yes	8.37	19.7	14.1	B1
2	CD3⁺CD4⁺CD26⁻	Yes	2	Yes	179.0	8.6	80.2	B2
3	CD3⁺CD4⁺CD26⁻	Yes	12	Yes	2.12	8.9	34.3	B2
4	CD3⁺CD4⁺CD7⁻CD26⁻	Yes	Indirect	No	8.11	14.3	38.5	B2
5	CD3⁺CD4⁺CD26⁻	Yes	16	Yes	15.6	10	71.5	B2
6	CD3⁺CD4⁺CD7⁻CD26⁻	Yes	1	Yes	28.69	86.2	84.5	B2
7	CD3⁺CD4⁺CD7⁻CD26⁻	Yes	13.6	None	56.81	83.9	58.7	B2
8	CD3⁺CD4⁺CD7⁻CD26⁻	Yes	12	Yes	24.78	54.9	71.4	B2
9	CD3⁺CD4⁺CD7⁻CD26⁻	N/A	N/A	Yes	10.22	38.9	36.5	B2
10	CD3⁺CD4⁺CD7⁻CD26⁻	Yes	13.1	Yes	7.06	44.3	25.5	B2
11	CD3⁺CD4⁺CD26⁻	Yes	13.6	Yes	9.66	11.4	46	B2
12	CD3⁺CD4⁺CD26⁻	Yes	Indirect	Yes	5.18	1.9	48.5	B2
13	CD3⁺CD4⁺CD7⁻CD26⁻	Yes	21.3	Yes	59.63	89.8	88.7	B2
14	CD3⁺CD4⁺CD26⁻	No	None	Yes	4.45	16.2	4.8	B1
15	CD3⁺CD4⁺CD7⁻CD26⁻	Yes	Indirect	Yes	6.95	63.9	62.6	B2
16	CD3⁺CD4⁺CD7⁻CD26⁻	Yes	Indirect	Yes	20.02	87.2	76.3	B2
17	CD3⁺CD4⁺CD7⁻CD26⁻	Yes	7.2	Yes	4.7	30.4	33.8	B2
18	CD3⁺CD4⁺CD7⁻CD26⁻	Yes	7.2	Yes	3.74	27.4	26.0	B1
19	CD3⁺CD4⁺CD7⁻CD26⁻	No	None	No	1.21	20.6	22.5	B1
20	CD3⁺CD4⁺CD7⁻CD26⁻	Suspicion	Indirect	Yes	1.63	22.5	24.5	B1
21	CD3⁺CD4⁺CD7⁻CD26⁻	Suspicion	5.3	None	4.75	69.6	71.8	B2
22	CD3⁺CD4⁺CD7⁻CD26⁻	Suspicion	17	Yes	1.75	19.9	18.5	B1
23	CD3⁺CD4⁺CD26⁻	Yes	2	Yes	27.91	51.1	89.5	B2
24	CD3⁺CD4⁺CD7⁻CD26⁻	Suspicion	Indirect	Yes	1.3	23.7	23.8	B1
25	CD3⁺CD4⁺CD7⁻CD26⁻	No	None	Yes	8.87	24.9	19.1	B1

Pt ID	Sorted abnormal cell population	TCR-Vβ⁺	Vβ gene identified	PCR⁺	CD4:CD8 ratio	CD4⁺CD7⁻, %	CD4⁺CD26⁻, %	Stage
1	CD3⁺CD4⁺CD7⁻CD26⁻	Yes	20	Yes	8.37	19.7	14.1	B1
2	CD3⁺CD4⁺CD26⁻	Yes	2	Yes	179.0	8.6	80.2	B2
3	CD3⁺CD4⁺CD26⁻	Yes	12	Yes	2.12	8.9	34.3	B2
4	CD3⁺CD4⁺CD7⁻CD26⁻	Yes	Indirect	No	8.11	14.3	38.5	B2
5	CD3⁺CD4⁺CD26⁻	Yes	16	Yes	15.6	10	71.5	B2
6	CD3⁺CD4⁺CD7⁻CD26⁻	Yes	1	Yes	28.69	86.2	84.5	B2
7	CD3⁺CD4⁺CD7⁻CD26⁻	Yes	13.6	None	56.81	83.9	58.7	B2
8	CD3⁺CD4⁺CD7⁻CD26⁻	Yes	12	Yes	24.78	54.9	71.4	B2
9	CD3⁺CD4⁺CD7⁻CD26⁻	N/A	N/A	Yes	10.22	38.9	36.5	B2
10	CD3⁺CD4⁺CD7⁻CD26⁻	Yes	13.1	Yes	7.06	44.3	25.5	B2
11	CD3⁺CD4⁺CD26⁻	Yes	13.6	Yes	9.66	11.4	46	B2
12	CD3⁺CD4⁺CD26⁻	Yes	Indirect	Yes	5.18	1.9	48.5	B2
13	CD3⁺CD4⁺CD7⁻CD26⁻	Yes	21.3	Yes	59.63	89.8	88.7	B2
14	CD3⁺CD4⁺CD26⁻	No	None	Yes	4.45	16.2	4.8	B1
15	CD3⁺CD4⁺CD7⁻CD26⁻	Yes	Indirect	Yes	6.95	63.9	62.6	B2
16	CD3⁺CD4⁺CD7⁻CD26⁻	Yes	Indirect	Yes	20.02	87.2	76.3	B2
17	CD3⁺CD4⁺CD7⁻CD26⁻	Yes	7.2	Yes	4.7	30.4	33.8	B2
18	CD3⁺CD4⁺CD7⁻CD26⁻	Yes	7.2	Yes	3.74	27.4	26.0	B1
19	CD3⁺CD4⁺CD7⁻CD26⁻	No	None	No	1.21	20.6	22.5	B1
20	CD3⁺CD4⁺CD7⁻CD26⁻	Suspicion	Indirect	Yes	1.63	22.5	24.5	B1
21	CD3⁺CD4⁺CD7⁻CD26⁻	Suspicion	5.3	None	4.75	69.6	71.8	B2
22	CD3⁺CD4⁺CD7⁻CD26⁻	Suspicion	17	Yes	1.75	19.9	18.5	B1
23	CD3⁺CD4⁺CD26⁻	Yes	2	Yes	27.91	51.1	89.5	B2
24	CD3⁺CD4⁺CD7⁻CD26⁻	Suspicion	Indirect	Yes	1.3	23.7	23.8	B1
25	CD3⁺CD4⁺CD7⁻CD26⁻	No	None	Yes	8.87	24.9	19.1	B1

Abnormal cell phenotype identified by flow cytometry as phenotypically atypical: TCR-Vβ⁺ if >50% of the population of atypical cells express a single Vβ, or by indirect evidence, if there is <20% expression of the entire 27 Vβ antibody panel.⁴⁴ PCR⁺ if ≥1 of 3 PCRs identifies a clone. B stage based on ISCL classification⁴³ and the 2016 criteria proposed by Gibson et al.⁴⁴ Patients staged as B2 have elevated absolute CD3⁺ or CD3⁺CD4⁺ cell counts, with the upper limits of normal defined as >2245 cells per microliter and >1612 cells per microliter, respectively. CD4⁺CD7⁻ and CD4⁺CD26⁻ percent specifications are defined as percentage of peripheral blood mononuclear cells (lymphocytes and monocytes).

N/A, not assessed; Pt ID, patient identifier.

View Large

This Feature Is Available To Subscribers Only